{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T22:26:24Z","timestamp":1788215184018,"version":"build-2803163510"},"reference-count":26,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T00:00:00Z","timestamp":1746748800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Health Serv."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>The stopping overmedication of people with a learning disability, autism, or both (STOMP) programme was launched in 2016 in response to concerns about the over-prescribing of medication in people with intellectual disability. The programmes focus has been on the withdrawal of antipsychotic treatment for the individual person than the service or dosage optimisation. It could be that cumulative service level antipsychotic treatment converted and presented as chlorpromazine units could allow for comparison of services on how antipsychotic treatment is being utilised and allow for comparing of practices between services in different regions. The aim of this feasibility study is to explore if cumulative service scores of antipsychotic treatment burden could define prescribing patterns across different specialist intellectual disability services in England and Wales, focused on those on \u22652 antipsychotic treatments. There is no evidence to use \u22652 antipsychotic treatments for any individual.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The study is a feasibility cross-sectional study investigating service antipsychotic treatment cumulative burden at seven annual time points, 2017\u20132023. De-identified data for adult patients with intellectual disability under the care of specialist intellectual disability services in receipt of \u22652 oral and\/or long-acting IM (intramuscular) injectable (depot) antipsychotic treatments are included. Demographic and clinical data will be collated, in addition to information on the prescribed antipsychotic treatments. The data will be evaluated for data completeness and will be inputted into the Statistical Process Control tool. Outcomes will be measured using a combination of methods including descriptive analysis (including mean, standard deviation and percentage values), and a mixed effects regression model, to determine changes in chlorpromazine equivalent dose values over time.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Seven England and Wales National Health Service intellectual disability services are recruiting up to 490 people. There were recognised challenges in identifying the relevant eligible cohort across services and administering a common set of outcome measures.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>This study is intended to inform decisions to design a wider registry that would involve antipsychotic treatment prescribing data for patients across multiple sites nationwide. Developing a de-identified database using routinely collected data, without the requirement for informed consent, comes with unique benefits and challenges.<\/jats:p><\/jats:sec><jats:sec><jats:title>Registry reference<\/jats:title><jats:p>NCT06238089 (<jats:ext-link>www.clinicaltrials.gov<\/jats:ext-link>).<\/jats:p><\/jats:sec>","DOI":"10.3389\/frhs.2025.1393805","type":"journal-article","created":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T05:37:52Z","timestamp":1746769072000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["A novel way to understand and communicate the burden of AntiPsycHotic prescribing for adults across specialist Intellectual Disability services in England and Wales: the APHID feasibility study protocol"],"prefix":"10.3389","volume":"5","author":[{"given":"Emily","family":"Stanyard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Neilens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Allgar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Bailey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Crispin","family":"Musicha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiran","family":"Purandare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhathika","family":"Perera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashok","family":"Roy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Indermeet","family":"Sawhney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lance","family":"Watkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sujeet","family":"Jaydeokar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Lennard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"McGowan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Laugharne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel J.","family":"Tromans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohit","family":"Shankar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,5,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1352\/1944-7558-126.6.439","article-title":"An overview of intellectual disability: definition, diagnosis, classification, and systems of support","volume":"126","author":"Schalock","year":"2021","journal-title":"Am J Intellect Dev Disabil"},{"key":"B2","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.ridd.2010.12.018","article-title":"Prevalence of intellectual disability: a meta-analysis of population-based studies","volume":"32","author":"Maulik","year":"2011","journal-title":"Res Dev Disabil"},{"key":"B3","volume-title":"Psychotropic Drugs and People with Learning Disabilities or Autism","author":"Mehta","year":"2019"},{"key":"B4","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1111\/j.1468-3148.2006.00293.x","article-title":"The prevalence of psychiatric disorders among people with intellectual disabilities: an analysis of the literature","volume":"19","author":"Whitaker","year":"2006","journal-title":"J Appl Res Intellect Disabil"},{"key":"B5","doi-asserted-by":"publisher","first-page":"h4326","DOI":"10.1136\/bmj.h4326","article-title":"Mental illness, challenging behaviour, and psychotropic drug prescribing in people with intellectual disability: UK population based cohort study","volume":"351","author":"Sheehan","year":"2015","journal-title":"Br Med J"},{"key":"B6","volume-title":"Stopping over medication of people with a learning disability, autism or both (STOMP)","year":""},{"key":"B7","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1192\/bjp.2022.34","article-title":"Antidepressant prescribing for adult people with an intellectual disability living in England","volume":"221","author":"Branford","year":"2022","journal-title":"Br J Psychiatry"},{"key":"B8","doi-asserted-by":"publisher","first-page":"e84","DOI":"10.1192\/bjo.2022.49","article-title":"International clinician perspectives on pandemic-associated stress in supporting people with intellectual and developmental disabilities","volume":"8","author":"Howkins","year":"2022","journal-title":"BJPsych Open"},{"key":"B9","doi-asserted-by":"publisher","first-page":"e128","DOI":"10.1192\/bjo.2020.122","article-title":"Priority concerns for people with intellectual and developmental disabilities during the COVID-19 pandemic","volume":"6","author":"Tromans","year":"2020","journal-title":"BJPsych Open"},{"key":"B10","doi-asserted-by":"publisher","first-page":"e7","DOI":"10.1192\/bjo.2021.1064","article-title":"COVID-19 pandemic impact on psychotropic prescribing for adults with intellectual disability: an observational study in English specialist community services","volume":"8","author":"Naqvi","year":"2022","journal-title":"BJPsych Open"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/bmjment-2023-300775","article-title":"Impact of the COVID-19 pandemic on antipsychotic prescribing in individuals with autism, dementia, learning disability, serious mental illness or living in a care home: a federated analysis of 59 million patients\u2019 primary care records in situ using OpenSAFELY","volume":"26","author":"Macdonald","year":"2023","journal-title":"BMJ Mental Health"},{"key":"B12","article-title":"Antipsychotic medications","volume-title":"StatPearls","author":"Chokhawala","year":"2023"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1111\/jar.12635","article-title":"A structured programme to withdraw antipsychotics among adults with intellectual disabilities: the Cornwall experience","volume":"32","author":"Shankar","year":"2019","journal-title":"J Appl Res Intellect Disabil"},{"key":"B14","volume-title":"The Maudsley Prescribing Guidelines in Psychiatry","author":"Taylor","year":"2018"},{"key":"B15","volume-title":"Statistical Process Control Tool","year":""},{"key":"B16","article-title":"North East London Foundation Trust","year":""},{"key":"B17","article-title":"Cheshire and Wirral Partnership NHS Foundation Trust","year":""},{"key":"B18","volume-title":"Central and North West London NHS Foundation Trust Inspection Report 04\/06\/2019","year":"2019"},{"key":"B19","volume-title":"Trust Values","year":"2021"},{"key":"B20","article-title":"Coventry and Warwickshire Partnership NHS Trust","year":""},{"key":"B21","article-title":"Hertfordshire Partnership University NHS Foundation Trust","year":""},{"key":"B22","volume-title":"A Quantitative Equality Analysis of the Demographic Profile of Service Users and Their Access to Services","year":""},{"key":"B23","article-title":"Swansea Bay University Health Board","year":""},{"key":"B24","volume-title":"British National Formulary","year":"2023"},{"key":"B25","doi-asserted-by":"publisher","first-page":"S90","DOI":"10.1093\/schbul\/sbv167","article-title":"Dose equivalents for antipsychotic drugs: the DDD method","volume":"42","author":"Leucht","year":"2016","journal-title":"Schizophr Bull"},{"key":"B26","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.schres.2013.06.030","article-title":"How to compare doses of different antipsychotics: a systematic review of methods","volume":"149","author":"Patel","year":"2013","journal-title":"Schizophr Res"}],"container-title":["Frontiers in Health Services"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/frhs.2025.1393805\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T05:37:55Z","timestamp":1746769075000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/frhs.2025.1393805\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,9]]},"references-count":26,"alternative-id":["10.3389\/frhs.2025.1393805"],"URL":"https:\/\/doi.org\/10.3389\/frhs.2025.1393805","relation":{},"ISSN":["2813-0146"],"issn-type":[{"value":"2813-0146","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,9]]},"article-number":"1393805"}}